7月13日 - ** 肿瘤治疗公司Erasca（ERAS.O）在盘后交易中股价下跌1.9%，至17.56美元，该公司正寻求融资
** ERAS 宣布 (link) 将进行5亿美元的股票发行
** 该公司计划将募集资金净额用于其候选产品的研发、其他开发项目以及营运资金等一般用途
** 摩根大通、摩根士丹利、杰富瑞和Evercore担任联合簿记管理人
** 总部位于加利福尼亚州圣地亚哥的ERAS还公布了针对RAS基因突变所致实体瘤患者的ERAS-0015药物最新I期临床试验数据 (link)
** 4月下旬，ERAS公司表示一名患者在ERAS-0015的早期临床试验中死亡 (link)，其股价随后暴跌48%
** 周一，该公司股价收跌3.4%，报17.90美元，但年初至今累计上涨381%
** 据LSEG数据显示，11位分析师中有9位给予该股“强烈买入”或“买入”评级，2位给予“持有”评级；目标价中位数为20美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.